Unlock instant, AI-driven research and patent intelligence for your innovation.

Esters of l-carnitine of alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds

A technology of compounds, drugs, applied in the field of cationic lipids, which can solve the problems of failure to produce encouraging, failure of polynucleotide complexes, etc.

Inactive Publication Date: 2008-07-16
SIGMA TAU IND FARMACEUTICHE RIUNITE SPA
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0030] Attempts to stabilize polynucleotide complexes have so far failed to yield encouraging results; indeed, they remain stable only for short periods of time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Esters of l-carnitine of alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds
  • Esters of l-carnitine of alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds
  • Esters of l-carnitine of alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0115] Ester of propionyl L-carnitine bromide with 2-hydroxyacetyl-1,3-dipalmitoylglycerol (ST772)

[0116] a) Preparation of 1,3-dihydroxypropan-2-one 1,3-dipalmitate (1)

[0117] Dihydroxyacetone (7 g; 0.078 mol) was dissolved in 300 mL of dry chloroform at 0°C (external temperature) under a stream of dry nitrogen.

[0118] To the resulting solution were added palmitoyl chloride (44 g; 0.16 mol) and anhydrous pyridine (15 mL) dropwise.

[0119] The resulting mixture, which had been warmed to ambient temperature, was stirred for 24 hours.

[0120] The mixture was extracted in the following order: 300 mL of 0.5% aqueous hydrochloric acid, 300 mL of 5% aqueous sodium bicarbonate, and finally 300 mL of water.

[0121] The separated organic phase was dehydrated with anhydrous sodium sulfate, filtered through a cellulose filter and concentrated to dryness to give crude product (1).

[0122] Crystallization from 500mL ethanol gave pure product.

[0123] 30.4 g of product (1) ar...

example 2-7

[0161] Prepare the following compounds in the same manner as in the above examples:

[0162] - Esters of L-carnitine bromide and 2-hydroxyacetyl-1,3-dipalmitoylglycerol (ST770);

[0163] - Esters of acetyl L-carnitine bromide with 2-hydroxyacetyl-1,3-dipalmitoylglycerol (ST 771);

[0164] - Esters of isobutyryl L-carnitine bromide and 2-hydroxyacetyl-1,3 dipalmitoylglycerol (ST 773);

[0165] - Ester of isovaleryl L-carnitine bromide with 2-hydroxyacetyl-1,3-dipalmitoylglycerol (ST 774);

[0166] - Ester of L-carnitine bromide with 1,3-dihexanoyl-2-hydroxyacetylglycerol (ST810);

[0167] - Esters of acetyl L-carnitine bromide with 1,3-dihexanoyl-2-hydroxyacetylglycerol (ST 809);

[0168] - ester of propionyl L-carnitine bromide with 1,3-dihexanoyl-2-hydroxyacetylglycerol (ST 808);

[0169] A preferred embodiment of the invention described here involves the preparation of liposomes with anticancer drugs, especially liposomes as carriers for camptothecin, as described in WO ...

example 8

[0194] 7-Benzyloxyiminomethylcamptothecin (CPT 172)

[0195] 500 mg (1.33 mmol) of 7-formylcamptothecin were dissolved in 100 ml of ethanol. 15 ml of pyridine and 638 mg (4 mmol) of O-benzylhydroxylamine hydrochloride were added. The solution was refluxed for 5 hours. The solvent was evaporated in vacuo and the resulting residue was purified by flash chromatography on silica gel with a 4:6 mixture of hexane and ethyl acetate as eluent.

[0196] Yield: 65%

[0197] Melting point: 200-205°C.

[0198] The product obtained contained a mixture of cis and trans isomers in a ratio of 8:2 (isomer A: Rf 0.32; isomer B, Rf 0.19, using Merck 60 F254 silica gel;

[0199] Eluent: hexane:ethyl acetate 3:7).

[0200] HPLC: The analysis was performed with an instrument equipped with a quaternary pump (HP1050), using a Rheodyne syringe (20 μl loop) and a diode array detector (HP 1050), driven using the HPLC-Chem Station program. Spectra were obtained in the range 200-600 nm and chromatog...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

Esters of L-carnitine and alkanoyl L-carnitines are described which can be used as cationic lipids for the intracellular delivery of pharmacologically active compounds. New esters of L-carnitine and alkanoyl L-carnitines of formula (I) are also disclosed wherein the R groups are as defined in the description.

Description

[0001] The present invention is the application number submitted on April 11, 2000 is 00807053.9 (PCT / IT00 / 00137), the title of invention is "L-carnitine or alkanoyl L as cationic lipid for intracellular release of pharmacologically active compounds -Ester of carnitine" is a divisional application of the Chinese patent application. technical field [0002] The present invention relates to a new class of esters of L-carnitines and acyl-L-carnitines and their use as esters suitable for aiding the intracellular release of pharmacologically active compounds, facilitating their transmembrane transport or facilitating their binding to specific cell membrane sites (receptors). ) Use of an interacting cationic lipid. [0003] The present invention also relates to other known esters of L-carnitines and acyl-L-carnitines which are used for the same purpose as the above-mentioned novel compounds. [0004] The term "intracellular release" means herein the transfection of cells (gene rele...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/127A61K47/16C07C229/00A61K8/00A61K8/11A61K8/14A61K8/30A61K8/37A61K8/44A61K31/225A61K31/337A61K31/4745A61K39/00A61K45/00A61K47/18A61K47/24A61K47/44A61K48/00A61P35/00A61Q19/00C07C229/02C07C229/22
CPCA61K9/127A61K48/00A61K9/0019A61K9/19C07C229/22A61K8/14A61K8/44A61Q19/00A61K9/1277A61K31/225A61K9/1272A61P31/00A61P35/00A61P37/00A61P37/04A61P9/00C07C229/02
Inventor C·匹萨诺M·O·廷提M·圣塔尼罗L·克里泰利G·萨尔瓦托利
Owner SIGMA TAU IND FARMACEUTICHE RIUNITE SPA